CN114650829A - 结合bcma的二聚体抗原受体(dar) - Google Patents

结合bcma的二聚体抗原受体(dar) Download PDF

Info

Publication number
CN114650829A
CN114650829A CN202080076523.8A CN202080076523A CN114650829A CN 114650829 A CN114650829 A CN 114650829A CN 202080076523 A CN202080076523 A CN 202080076523A CN 114650829 A CN114650829 A CN 114650829A
Authority
CN
China
Prior art keywords
seq
sequence
dar
region
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080076523.8A
Other languages
English (en)
Chinese (zh)
Inventor
H·H·吉
郭文忠
张延良
丁蓓蓓
G·F·考夫曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sorento Pharmaceutical Co ltd
Original Assignee
Sorento Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sorento Pharmaceutical Co ltd filed Critical Sorento Pharmaceutical Co ltd
Publication of CN114650829A publication Critical patent/CN114650829A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN202080076523.8A 2019-09-05 2020-09-04 结合bcma的二聚体抗原受体(dar) Pending CN114650829A (zh)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201962896190P 2019-09-05 2019-09-05
US62/896,190 2019-09-05
US201962896990P 2019-09-06 2019-09-06
US62/896,990 2019-09-06
US201962910341P 2019-10-03 2019-10-03
US62/910,341 2019-10-03
US201962943069P 2019-12-03 2019-12-03
US62/943,069 2019-12-03
US202063030145P 2020-05-26 2020-05-26
US63/030,145 2020-05-26
PCT/US2020/049538 WO2021046445A1 (en) 2019-09-05 2020-09-04 Dimeric antigen receptors (dar) that bind bcma

Publications (1)

Publication Number Publication Date
CN114650829A true CN114650829A (zh) 2022-06-21

Family

ID=74852154

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080076523.8A Pending CN114650829A (zh) 2019-09-05 2020-09-04 结合bcma的二聚体抗原受体(dar)

Country Status (10)

Country Link
US (1) US20220251168A1 (https=)
EP (1) EP4025227A4 (https=)
JP (1) JP2022546577A (https=)
KR (1) KR20220057598A (https=)
CN (1) CN114650829A (https=)
AU (1) AU2020341712A1 (https=)
CA (1) CA3149867A1 (https=)
IL (1) IL291076A (https=)
MX (1) MX2022002723A (https=)
WO (1) WO2021046445A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202109163YA (en) * 2019-02-26 2021-09-29 Sorrento Therapeutics Inc Antigen binding proteins that bind bcma
EP4139345A1 (en) 2020-04-24 2023-03-01 Sorrento Therapeutics, Inc. Memory dimeric antigen receptors
WO2022226364A2 (en) * 2021-04-23 2022-10-27 Sorrento Therapeutics, Inc. Dimeric antigen receptors (dars) that bind gd2
KR20240051280A (ko) * 2021-09-06 2024-04-19 젠맵 에이/에스 Cd27과 결합할 수 있는 항체, 그의 변이체 및 그의 용도
CN116655805B (zh) * 2023-05-31 2024-03-08 四川大学华西医院 一种靶向her2阳性肿瘤的新型car-t细胞及制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187158A1 (en) * 2015-05-15 2016-11-24 City Of Hope Chimeric antigen receptor compositions
US20180085457A1 (en) * 2015-10-23 2018-03-29 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
CN112105649A (zh) * 2018-03-09 2020-12-18 索伦托药业有限公司 二聚体抗原受体(dar)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015166056A1 (en) * 2014-05-02 2015-11-05 Cellectis Cs1 specific multi-chain chimeric antigen receptor
US11173179B2 (en) * 2015-06-25 2021-11-16 Icell Gene Therapeutics Llc Chimeric antigen receptor (CAR) targeting multiple antigens, compositions and methods of use thereof
US12195529B2 (en) * 2017-06-21 2025-01-14 Gsbio, Llc Heterodimeric bispecific antibodies
AU2018358067A1 (en) * 2017-11-01 2020-05-07 Juno Therapeutics, Inc. Antibodies and chimeric antigen receptors specific for B-cell maturation antigen
SG11202109163YA (en) * 2019-02-26 2021-09-29 Sorrento Therapeutics Inc Antigen binding proteins that bind bcma

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016187158A1 (en) * 2015-05-15 2016-11-24 City Of Hope Chimeric antigen receptor compositions
US20180085457A1 (en) * 2015-10-23 2018-03-29 Eureka Therapeutics, Inc. Antibody/t-cell receptor chimeric constructs and uses thereof
CN112105649A (zh) * 2018-03-09 2020-12-18 索伦托药业有限公司 二聚体抗原受体(dar)

Also Published As

Publication number Publication date
EP4025227A4 (en) 2023-11-01
KR20220057598A (ko) 2022-05-09
MX2022002723A (es) 2022-03-22
CA3149867A1 (en) 2021-03-11
JP2022546577A (ja) 2022-11-04
WO2021046445A1 (en) 2021-03-11
EP4025227A1 (en) 2022-07-13
US20220251168A1 (en) 2022-08-11
AU2020341712A1 (en) 2022-03-31
IL291076A (en) 2022-05-01

Similar Documents

Publication Publication Date Title
US20240294639A1 (en) Antigen-binding proteins targeting cd56 and methods of producing thereof
US12180294B2 (en) Dimeric antigen receptors
EP3875484A1 (en) Cll1-targeting antibody and application thereof
US20190225692A1 (en) Hpv-specific binding molecules
CA3111384A1 (en) Allogeneic cell compositions and methods of use
CN114650829A (zh) 结合bcma的二聚体抗原受体(dar)
EP4467567A1 (en) Anti-cd70 nanoantibody and use thereof
JP2019512207A (ja) Ｆｏｘｐ３由来のペプチドに特異的なｔ細胞受容体様抗体
CN116249559A (zh) 抗独特型组合物及其使用方法
CN110352197B (zh) 嵌合氯毒素受体
US20230061838A1 (en) Dimeric Antigen Receptors (DAR) That Bind CD20
CN116284389A (zh) 抗afp/hla02 tcr样抗体及其用途
US20240197881A1 (en) Dimeric Antigen Receptors (DARs) that Bind GD2
US20230167191A1 (en) Memory Dimeric Antigen Receptors (mDARs)
EP4620974A1 (en) Anti-afp/hla02 tcr-like antibody and use thereof
CN117545493A (zh) 与gd2结合的二聚体抗原受体（dar）

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220621